Prenosis, Inc., a precision diagnostics company transforming clinical diagnosis with predictive intelligence, announced today the expansion of an existing partnership with Roche Diagnostics that will total close to $6M to improve and expedite the clinical recognition of sepsis through advanced precision diagnostics. Building upon the collaboration that the companies started together in 2020, Prenosis will significantly expand its core NOSIS™ dataset, and the two companies will work together to obtain U.S. Food and Drug Administration (FDA) clearance for the Prenosis Sepsis Immunoscore™ and the Roche Elecsys® IL-6 Assay. These tools aim to provide physicians with powerful new solutions for fighting sepsis through early risk identification.
The Prenosis dataset, which features Elecsys IL-6 measurements, in addition to measurements of a diverse set of parameters representing several different dimensions of immune response, is the world’s largest and fastest growing hybrid biomarker-clinical dataset for sepsis care. The partnership drives the unique combination of a traditional diagnostic test with next generation predictive analytics, demonstrating the potential to usher in a new era of holistic digital diagnostics for more comprehensive profiling of complex heterogeneous hospital conditions.
According to the World Health Organization, more than 11 million people die from sepsis worldwide annually, more than the deaths caused by all cancers combined. Studies show that sepsis is the leading cause of death in U.S. hospitals, with total annual costs of treatment and rehabilitation estimated at $62 billion.1 Before the COVID-19 pandemic, at least 1.7 million adults in the United States developed sepsis annually. During the pandemic, this problem was greatly exacerbated, as most COVID-19 deaths are due to viral and/or bacterial sepsis.2